DARE News and Press, Dare Bioscience Inc. From 11/01/23

Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction Achieved Statistical Significance and Clinically Meaningful Improvement in Phase 2b Co-Primary Endpo...

2023-10-16 10:59:42 ET More on Dare Bioscience Seeking Alpha’s Quant Rating on Dare Bioscience Dare Bioscience to sell 10M shares at $0.70 in registered direct offering Historical earnings data for Dare Bioscience For further details see: Daré...

SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% in connection with the first commercial sale of...

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré&...

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The...

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following investor conferences in September 20...

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rule...

2023-08-30 09:07:03 ET More on Dare Bioscience Daré Bioscience, Inc. 2023 Q2 - Results - Earnings Call Presentation Daré Bioscience, Inc. ( DARE ) Q2 2023 Earnings Call Transcript Daré Bioscience hits seven-month high after regaining listing compli...

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has entered into a definitive agreement with an institutional investor and an investor affiliated with the licensor of one of the comp...

2023-08-10 19:54:04 ET Daré Bioscience, Inc. (DARE) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Commercial Officer Lisa Walters-Hoffert - ...